Fujian Aonong Biological Technology Group Incorporation Ltd (603363) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Fujian Aonong Biological Technology Group Incorporation Ltd stock ¥0.43, price ¥2.69, that is 83.9% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range ¥2.56 – ¥26.65 · fair‑value band ¥0.2805 – ¥0.6375 · the ¥2.69 price screens above the ¥0.4335 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.
Follow Fujian Aonong Biological Technology Group Incorporation in your weekly email
Every Wednesday you see whether Fujian Aonong Biological Technology Group Incorporation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Fujian Aonong Biological Technology Group Incorporation Limited engages in the feed, pig farming, food, supply chain services, and other businesses in China and internationally.
Show moreShow less
It researches and develops, produces, and sells feed products, such as pig feed, poultry feed, aquatic feed, ruminant feed, and other products; operates pig breeding farms; and engages in the pig slaughtering and processing activities, as well as raw materials trade.
The company offers feed, live pigs, pork and meat products, as well as creates pig OK management platform. Fujian Aonong Biological Technology Group was founded in 2011 and is based in Zhangzhou, China.
Stock analysis
Fujian Aonong Biological Technology Group Incorporation Ltd (603363) currently trades at ¥2.69, while our model-based Fair Value estimate is ¥0.4335, 84% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥1.17 per share, and 1 of the 12 models we run sit above the ¥2.69 price.
Bear case: the Earnings-Based group reads lowest at ¥0.2650, and 11 of the 12 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.2805 (bear) to ¥0.6375 (bull), the price of ¥2.69 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Fujian Aonong Biological Technology Group Incorporation Ltd reported revenue of 8.5B CNY in FY2025 versus 18.0B CNY in FY2021, a compound −17.2%/yr. Reported net income was 77.6M CNY in FY2025.
Key figures
Market cap 7.0B CNY (≈ $1.1B) Small · P/S ratio 0.82 · EPS (TTM) ¥−0.1800 · Dividend yield 1.1% · Net margin −5.2% · Return on equity −16.0% · Return on assets (EBIT) −8.1% (5-year average) · Operating margin −8.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).
What moves the price
The share trades about 54% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 6% fair-value upside, at −84%, 603363 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.1000 to ¥4.39). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥0.2805Fair Value ¥0.4335Bull¥0.6375
Price ¥2.69 · Downside -83.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings¥0.3200¥0.5100¥0.750076
Residual Income¥0.7500¥0.7600¥0.790076
Gordon GGM¥0.2500¥0.3800¥0.500069
All 12 models by family
DCF Models
Owner Earnings¥0.3200¥0.5100¥0.750076
Earnings-Based
Graham-Dodd¥0.1900¥0.4300¥0.540066
PEG = 1.0¥0.0700¥0.1000¥0.130057
Dividend Discount
Gordon GGM¥0.2500¥0.3800¥0.500069
DDM Multi-Stage¥0.2500¥0.3500¥0.450067
Multiples
P/E Multiple¥0.4500¥0.6000¥0.750063
P/S Multiple¥0.3600¥0.4800¥0.600058
P/B Multiple¥3.30¥4.39¥5.4955
EV/EBITDA¥1.22¥1.74¥2.2667
Asset-Based
NCAV (Graham)¥0.4500¥0.6100¥0.910054
Economic Profit
Residual Income¥0.7500¥0.7600¥0.790076
Growth Earnings
Growth-Adj P/E¥0.3300¥0.4800¥0.620067
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−3.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.0%
Start year 2020 (pandemic). Over 10 years: +7.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−41.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−42.7%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−42.7% vs −11.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → −1%
Compare Fujian Aonong Biological Technology Group Incorporation Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 291 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside−83.9% · Bottom 25%
Profitability
Return on assets0.9% · Below median
Net margin (12 months)−5.2% · Bottom 25%
Operating margin (12 months)−8.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)6.5% · Above median
Dividend yield (12 months)1.1% · Below median
Balance sheet
Debt / equity0.41× · Highest 25%
Valuation Multiplesvs Farm Products median · lower = cheaper
P/B2.24× · Priciest 25%
P/S (12 months)0.78× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 27
FUTURE (revenue growth)33· sector 15
PAST (return on equity)0· sector 17
HEALTH (low debt)80· sector 94
DIVIDEND (yield)23· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Fujian Aonong Biological Technology Group Incorporation Ltd Fair Value". https://www.fairvalue-calculator.com/stock/603363
Frequently asked questions
Is Fujian Aonong Biological Technology Group Incorporation Ltd (603363) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥0.4335 versus a price of ¥2.69, about 84% lower (overvalued).
What is the fair value of 603363?
Our model-based fair value for Fujian Aonong Biological Technology Group Incorporation Ltd is ¥0.4335 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥2.69.
What is the quality score of 603363?
Fujian Aonong Biological Technology Group Incorporation Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
Our model-based price target is the fair value of ¥0.4335 (as of Nov 5, 2026) from 12 valuation models. Cautious scenario ¥0.2805, optimistic scenario ¥0.6375. It is a calculation from audited fundamentals, not an analyst target.
What is the Fujian Aonong Biological Technology Group Incorporation Ltd stock forecast for 2026?
Our models put fair value at ¥0.4335, about 84% lower versus a price of ¥2.69 (overvalued). Cautious scenario ¥0.2805, optimistic scenario ¥0.6375. The calculation is refreshed regularly with new filings.
What is the revenue of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
Fujian Aonong Biological Technology Group Incorporation Ltd reported trailing-twelve-month revenue of about 9.0B CNY (latest available figure, as of Nov 5, 2026).
Does Fujian Aonong Biological Technology Group Incorporation Ltd pay a dividend?
Fujian Aonong Biological Technology Group Incorporation Ltd currently shows a dividend yield of 1.14% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
Fujian Aonong Biological Technology Group Incorporation Ltd has a dividend yield of 1.1%.
What is the intrinsic value of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fujian Aonong Biological Technology Group Incorporation Ltd it is ¥0.4335 per share (as of Nov 5, 2026), against a price of ¥2.69. It is the blended result of 12 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Fujian Aonong Biological Technology Group Incorporation Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 603363 trades above its calculated fair value: price ¥2.69, fair value ¥0.4335, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603363?
No. The price is what the market pays today (¥2.69); the fair value is what the company's own numbers justify (¥0.4335). For Fujian Aonong Biological Technology Group Incorporation Ltd the two are ¥2.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fujian Aonong Biological Technology Group Incorporation Ltd worth?
The market values Fujian Aonong Biological Technology Group Incorporation Ltd at about 7.0B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥2.69; our models calculate a fair value of ¥0.4335 per share.
What do the bullish and bearish scenarios say about 603363?
Our models span a range for Fujian Aonong Biological Technology Group Incorporation Ltd: cautious scenario ¥0.2805, base ¥0.4335, optimistic ¥0.6375 per share (as of Nov 5, 2026, price ¥2.69). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
Balance-sheet figures for Fujian Aonong Biological Technology Group Incorporation Ltd (as of Nov 5, 2026): return on equity −16.0%, debt of 0.41 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 603363 from its 52-week high?
Fujian Aonong Biological Technology Group Incorporation Ltd trades at ¥2.69, about 54% below its 52-week high of ¥5.80 and 5% above the low of ¥2.56 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.4335 is for.
Which stocks are comparable to Fujian Aonong Biological Technology Group Incorporation Ltd?
From the same area (Consumer Defensive) we also value Muyuan Foods Group, Archer-Daniels-Midland Company, Tyson Foods, Inc, Bunge Global SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fujian Aonong Biological Technology Group Incorporation Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price ¥2.69, calculated fair value ¥0.4335 (−84%), Quality Score 35/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603363 calculated?
We run Fujian Aonong Biological Technology Group Incorporation Ltd through 12 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥0.4335 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Fujian Aonong Biological Technology Group Incorporation Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
The closing price on Nov 6, 2026 was ¥2.69. Our model-based fair value is ¥0.4335, about 84% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fujian Aonong Biological Technology Group Incorporation Ltd right now?
The price sits above even our optimistic bull case (¥0.6375). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥0.2805 to ¥0.6375) leaves room in how you read the outcome.
Key figures of Fujian Aonong Biological Technology Group Incorporation Ltd
How large is the market capitalisation of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
The market capitalisation of Fujian Aonong Biological Technology Group Incorporation Ltd is 7.0B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
The price-to-sales ratio of Fujian Aonong Biological Technology Group Incorporation Ltd is 0.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
Earnings per share at Fujian Aonong Biological Technology Group Incorporation Ltd are ¥−0.1800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
The dividend yield of Fujian Aonong Biological Technology Group Incorporation Ltd is 1.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
The net margin of Fujian Aonong Biological Technology Group Incorporation Ltd is −5.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
The return on equity (ROE) of Fujian Aonong Biological Technology Group Incorporation Ltd is −16.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
On an EBIT basis the return on assets of Fujian Aonong Biological Technology Group Incorporation Ltd is −8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
The operating margin of Fujian Aonong Biological Technology Group Incorporation Ltd is −8.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
Revenue at Fujian Aonong Biological Technology Group Incorporation Ltd is growing +6.5% versus a year earlier (3y avg −26.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fujian Aonong Biological Technology Group Incorporation Ltd (603363)?
Earnings per share at Fujian Aonong Biological Technology Group Incorporation Ltd are growing −18.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Fujian Aonong Biological Technology Group Incorporation Ltd (603363) generate?
The free cash flow of Fujian Aonong Biological Technology Group Incorporation Ltd is −77.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Fujian Aonong Biological Technology Group Incorporation Ltd (603363) carry?
The net debt of Fujian Aonong Biological Technology Group Incorporation Ltd is 880M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Fujian Aonong Biological Technology Group Incorporation Ltd in the live analysis
One click puts Fujian Aonong Biological Technology Group Incorporation Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026